Scientists from the University of Leeds, in collaboration with researchers from the Institute of Ophthalmology in London and Ghent University in Belgium, have discovered that mutations in the gene…
‘The Dress’: studies offer insight as to why we are unable to agree on its color
The picture of ‘The Dress’ confused the world back in February. While some of us say it is blue and black, others see it as white and gold. Now, three new studies investigate why.
Uncategorized
Company Profile for Iris Pharma
–(BUSINESS WIRE)–A leading CRO dedicated to ophthalmology, Iris Pharma partners with clients to carry out preclinical and clinical studies involving all areas of the field.
X-82 to Treat Age-related Macular Degeneration
Status: Recruiting,
Condition Summary: Age-Related Macular Degeneration (AMD); Macular Degeneration; Exudative Age-related Macular Degeneration; AMD; Macular Degeneration, Age-related, 10; Eye Diseases; Retinal Degeneration; Retinal Diseases
Uncategorized
Preliminary phase 4 study data show good results of Jetrea in specific group of patients
PARIS — A multicenter phase 4 study evaluated the functional and anatomic outcomes of Jetrea in patients with focal vitreomacular traction and no epiretinal membranes. “Previous phase 3 studies demonstrated that best responders fell within these two categories, and it was thanks to the results of this group of patients that the ocriplasmin could be registered,” Laurent Kodjikian, MD, said at the meeting of the French Society of Ophthalmology.
Uncategorized
R&D expenses increase as Ophthotech advances Fovista clinical trials
Burgeoning patient enrollment for clinical trials of Fovista, Ophthotech’s leading product candidate, largely shaped the company’s balance sheet for the first quarter of 2015.During a company-sponsored conference call to report first quarter financial results and ongoing enrollment in the trials, CEO David R. Guyer, MD, discussed efforts to advance Fovista, an anti-PDGF agent, in the treatment of wet age-related macular degeneration.